Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06890611 · ClinicalTrials.gov registry record · Phase 1
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
NCT06890611: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT06890611 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 125 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (108% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06890611, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
Interventions
- DRUG Tirzepatide
- DRUG Bimagrumab
- DRUG Bimagrumab + Tirzepatide Coformulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 1 |
What the finished NCT06890611 record still lists
NCT06890611 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (108% higher).
The record links to 0 conditions, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06890611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06890611 about?
NCT06890611 is a clinical study titled "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants". The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.
What is the current status of trial NCT06890611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2025-03-25. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT06890611?
The interventions under investigation include: Tirzepatide (DRUG), Bimagrumab (DRUG), Bimagrumab + Tirzepatide Coformulation (DRUG).
Who is sponsoring clinical trial NCT06890611?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06890611's enrollment target sits among peer trials
125 467th of 2000 higher than 1,530 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI